Loading data for IMNN — first visit, this takes a few seconds.

알림

Imunon Inc. (IMNN)

NasdaqCM: IMNN · 실시간 가격 · USD

1.58

-0.02 (-1.25%)

종가 기준: Aug 18, 2026, 3:53 PM

-1.25% (1D)

매수호가	n/a
시가총액	8.87M
매출 (ttm)	n/a
순이익 (ttm)	-14.73M
베타	1.97
EPS (ttm)	-2.85
P/E (ttm)	n/a
선행 P/E	-0.89
P/B (ttm)	3.81
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	n/a
거래량	37,467
평균 거래량 (20일)	124,190
시가	1.61
전일 종가	1.60
일중 범위	1.54 - 1.61
52주 범위	1.47 - 6.96
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IMNN 소개

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a C...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 1, 1999

직원 수 20

상장 거래소 NasdaqCM

티커 IMNN

웹사이트 https://imunon.com

전체 기업 정보

재무 실적

2025년 Imunon의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -14.5M로, -22.15% 감소했습니다.

재무제표

어닝 서프라이즈

Imunon가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.54 예상치 상회 0.37, 및 71.12% 전년 대비 성장.

뉴스

1주 전 · Motley Fool

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Phase 2 ovarian cancer data shows 45.1-month survival versus 30.4 months in control arm.

1주 전 · Moby

Imunon, Inc. Q2 2026 Earnings Call Summary

Moby summary of Imunon, Inc.'s Q2 2026 earnings call

2주 전 · Benzinga

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

Clinical-stage biotechnology firm Imunon Inc. (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patien...

4주 전 · Benzinga

Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients

Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that ...

2개월 전 · InvestorsHub

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) traded higher in premarket dealings on Thursday after announcing a $10 million financing package that will support the continued development of its lead ovarian cancer progra...

2 페이지 중 1